BU-NOT-SET

CONTACT US
Women in leadership
  • Corporate
Eyes
Insight
The state of the oral solid dose development and manufacturing market
  • Drug product
Eyes
Insight
Characterising APIs is Essential for Combo Drug Formulations
  • Drug substance
Eyes
Insight
Outsourcing stability testing
  • Analytical chemistry
Eyes
Insight
Brexit: What’s next for UK pharma?
  • Industry trends
Eyes
Insight
Navigating approval filings choppy international waters
  • Drug substance
Eyes
Insight
Regulatory requirements for drug substances
  • Drug substance
Product check
Insight
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
Insight
  • Industry trends
Global expansion in the CDMO field
Fact sheet
  • Drug product
Fixed dose combinations - for improved patient compliance
Insight
  • Industry trends
The current state of contract manufacturing